查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1867124

黏液囊炎治疗市场按治疗方法、产品类型、应用部位和最终用户划分－2025-2032年全球预测

Bursitis Treatment Market by Treatment Type, Product Category, Application Site, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，黏液囊炎治疗市场将成长至 118.2 亿美元，复合年增长率为 4.77%。

主要市场统计数据
基准年 2024 81.4亿美元
预计年份：2025年 85.4亿美元
预测年份：2032年 118.2亿美元
复合年增长率 (%) 4.77%

简要介绍黏液囊炎的治疗途径、患者负担、跨专业协作以及影响当代临床实践的系统性因素。

黏液囊炎是一种常见但常被漏诊的疾病，它会导致不同患者族群疼痛和功能障碍。临床表现多样，从急性发炎发作到慢性、活动受限的疾病，后者会影响工作和休閒活动。治疗策略包括保守的自我护理、药物治疗、影像导引註射、復健干预，以及在特定情况下进行手术。人口结构的变化，包括人口老化、耐力运动和高强度运动参与度的提高，以及持续高发生率的代谢性疾病和风湿性疾病合併症，都增加了疾病诊疗的复杂性。

变革性的临床、技术和供应趋势正在奖励黏液囊炎管理中的治疗决策、护理服务模式和相关人员的激励机制。

过去几年，由于临床创新、医疗服务模式的演变以及相关人员期望的改变，黏液囊炎的治疗模式发生了显着变化。再生医学和生物目标疗法的进步为传统的皮质类固醇疗法提供了替代方案，而成像技术和超音波引导技术的进步则提高了注射治疗的精准性和安全性。同时，微创手术技术，特别是关节镜手术，优化了手术适应症，并缩短了合适患者的復原时间。

美国近期关税措施对黏液囊炎治疗管道的采购、价格压力、供应弹性和治疗方法可近性的影响

美国近期关税调整正对整个医疗保健供应链和药品价值链产生连锁反应，其累积效应影响治疗方案的可近性、采购方式和成本结构。进口医疗设备、注射剂和生技药品原料的关税上涨推高了部分产品的到岸成本，促使供应链相关人员重新评估筹资策略。因此，一些製造商和经销商正在加速供应商网路的多元化，考虑将关键零件的生产转移到近岸或回流，并协商其他商业条款以维持利润率并确保向医疗保健机构稳定供应。

清楚了解治疗方法、产品类别、解剖应用部位和临床环境对于解释应用模式和临床工作流程至关重要。

从细分观点，我们可以发现治疗方法应用、最活跃的相关人员以及创新领域整合的重要细微差别。从治疗方法方式来看，照护范围涵盖了从冰敷、休息和煞车、热敷等家庭措施，到包括非处方和处方非类固醇消炎剂在内的药物治疗，再到以皮质类固醇注射为主的注射疗法，以及透明质酸和富血小板血浆疗法等新兴疗法。物理治疗包括冷疗、运动疗法和手法治疗。同时，外科手术通常分为关节镜和开放性手术。每个细分领域都呈现出独特的模式。保守的居家照护和口服药物通常作为初始步骤，优先考虑可及性和低成本；而当症状持续或功能目标需要更积极的治疗时，通常会选择注射疗法和外科手术。

关键区域差异，包括实践模式、报销方式、监管管道和供应链因素，影响全球主要市场的临床应用

区域趋势对黏液囊炎的诊断、治疗和报销方式有显着影响，各大区域呈现不同的模式。在美洲，人们往往更重视快速获得介入治疗和完善的门诊管道，而私人医疗覆盖范围和日间手术中心的扩张则影响注射疗法和关节镜疗法的分布。在欧洲、中东和非洲，报销系统、管理体制以及先进生技药品取得途径的区域差异导致了实践差异较大。在许多市场，集中采购和统一的国家指南促使人们采用高成本的治疗方法，而公共医疗体系在製定治疗标准方面发挥着举足轻重的作用。在亚太地区，人口结构趋势，例如一些国家人口快速老化以及另一些国家较高的体育参与率，正在推动对保守治疗和介入治疗的需求。同时，製造地和区域供应链也影响药品的供应和定价趋势。

在黏液囊炎治疗及相关服务的商业性格局中，竞争角色、策略联盟和以证据为基础的差异化策略进行了深入分析。

黏液囊炎治疗生态系统的竞争动态呈现出多元化的参与企业组成，其中包括成熟的製药企业、医疗设备公司、生物製剂和再生医学研发企业、数位医疗供应商以及支持分销和临床培训的服务供应商。现有企业凭藉其规模、临床关係和丰富的产品系列，维持与医院和门诊中心的合作关係。同时，小规模的专业公司则专注于利基创新，特别是再生医学注射、照护现场生技药品处理和新型给药系统。此外，数位治疗方法和远距復健服务提供者也日益受到重视，它们能够帮助患者长期坚持运动方案，并促进远距临床医生的指导。

为製造商、医疗服务提供者和支付方提供切实可行的、以证据为基础的策略建议，以提高临床价值、增强供应韧性并改善以患者为中心的治疗效果。

产业领导者和临床计画负责人应采取多管齐下的策略，以充分发挥临床价值、改善患者疗效并降低商业性风险。首先，优先考虑新型注射疗法和再生医学方案的高品质证据至关重要。将随机对照试验与务实的真实世界研究结合，将有助于加强与支付方的合作，并促进指南的采纳。其次，供应链多元化以及探索关键零件的近岸外包方案，可以降低关税波动和运输中断带来的风险。同时，与集团采购组织达成策略协议，有助于稳定价格和供应。第三，投资临床医生教育以及超音波引导注射和微创手术的结构化实施项目，将有助于促进这些技术的合理应用，并降低疗效的差异性。

本研究采用严谨的混合方法调查方法，结合专家访谈、临床文献综合、供应链分析和利用资料三角验证，以确保研究结果的可靠性。

支持这些发现的研究采用了多层次的调查方法，对临床实践模式、采购行为和创新趋势进行三角验证。主要资料来源包括对骨科医生、物理治疗师、介入性疼痛专家、门诊手术经理和支付方医疗总监进行结构化访谈，以收集他们对治疗选择、实施障碍和营运限制的现场观点。次要分析则利用同行评审的临床文献、专业学会指南和监管文件，评估药物、注射和康復手术方法的相对证据基础。供应链图谱和贸易数据分析揭示了采购方面的脆弱性以及关税波动对零件供应的潜在影响。

摘要重点阐述了临床创新、医疗服务模式转型、支付方压力和医疗资源韧性这四者如何共同塑造黏液囊炎治疗的未来。

总而言之，黏液囊炎的治疗管理正受到多种因素的共同影响：生技药品和影像引导介入治疗的创新、远距和居家照护的普及、支付方对疗效和成本效益日益重视，以及供应链压力对产品供应和定价的影响。这些动态既给临床和商业领域的相关人员带来了挑战，也带来了机会。临床医师需要在整合新治疗方法的同时，维持实证治疗管道；製造商必须展现出明显的比较优势；医疗系统必须制定稳健的筹资策略，以支持患者持续获得全面的医疗服务。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大超音波引导下皮质类固醇注射的应用范围，以提高黏液囊炎治疗的准确性
  • 扩大微创针刺术的应用范围，以加快滑囊癒合并缩短恢復时间
  • 开发一种新型长效透明质酸配方，用于缓解肩部和髋部黏液囊炎疼痛
  • 将穿戴式运动感测器整合到黏液囊炎復健通讯协定中，用于即时监测关节负荷
  • 运动医学专业人士对富血小板血浆疗法治疗难治性滑囊炎的兴趣日益浓厚
  • 扩大家用冷却和加压系统（具备智慧温控功能）在黏液囊炎发炎管理的应用

第六章美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章 依治疗方法的黏液囊炎治疗市场

  • 居家照护
    • 冷疗
    • 卧床休息
    • 热敷
  • 注射疗法
    • 皮质类固醇注射
    • 玻尿酸注射
    • 富血小板血浆疗法
  • 口服药物
    • 非处方非类固醇消炎剂
    • 处方笺非类固醇消炎剂
  • 物理治疗
    • 冷冻疗法
    • 运动疗法
    • 手法治疗
  • 手术介入
    • 关节镜手术
    • 开放性手术

第九章 依产品类型的黏液囊炎治疗市场

  • 抗生素
  • 生技药品
  • 皮质类固醇
  • 非类固醇消炎剂

第十章黏液囊炎

  • 弯头
  • 脚跟
  • 髋关节
  • 膝盖
  • 肩膀

第十一章 以最终用户分類的黏液囊炎治疗市场

  • 门诊手术中心
  • 居家医疗环境
  • 医院
  • 整形外科诊所
  • 运动医学中心

第十二章 各地区黏液囊炎治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章黏液囊炎治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国黏液囊炎治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Pfizer Inc.
    • Bayer AG
    • Johnson & Johnson
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.
    • GlaxoSmithKline plc
    • Sanofi SA
    • Merck & Co., Inc.
    • Zimmer Biomet Holdings, Inc.
    • Stryker Corporation
Product Code: MRR-5D693B46C73C

The Bursitis Treatment Market is projected to grow by USD 11.82 billion at a CAGR of 4.77% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 8.14 billion
Estimated Year [2025] USD 8.54 billion
Forecast Year [2032] USD 11.82 billion
CAGR (%) 4.77%

A concise introduction to bursitis treatment pathways, patient burden, multidisciplinary care, and the systemic forces shaping contemporary clinical practice

Bursitis represents a common yet often underestimated source of pain and functional limitation across diverse patient populations. In clinical practice, presentations range from acute inflammatory flares to chronic, activity-limiting conditions that impair work performance and recreational participation. Management strategies span conservative self-care measures, pharmacologic treatment, image-guided injections, rehabilitative interventions, and, in select cases, surgical procedures. Demographic shifts such as population aging, rising participation in endurance and high-impact sports, and persistent rates of comorbid metabolic and rheumatologic conditions have collectively increased the complexity of care pathways for this condition.

In addition, evolving expectations around rapid recovery, minimally invasive approaches, and minimized opioid exposure shape both clinician decision-making and payer scrutiny. Care delivery has also been altered by expanded remote care modalities; patients increasingly seek timely advice and guided rehabilitation that reduce the need for in-person visits. Moreover, the growing emphasis on outcomes, functional restoration, and cost-effective care has prompted multidisciplinary collaboration among primary care physicians, orthopedic specialists, physiotherapists, and pain management teams. This introduction sets the stage for a deeper examination of market dynamics, treatment innovations, reimbursement influences, and operational pressures that together define the contemporary landscape of bursitis treatment.

Transformative clinical, technological, and supply dynamics that are redefining treatment decisions, care delivery models, and stakeholder incentives in bursitis management

Over the last several years, the treatment landscape for bursitis has undergone substantive transformation driven by clinical innovation, care delivery evolution, and shifting stakeholder expectations. Advances in regenerative medicine and targeted biologic therapies have introduced alternatives to traditional corticosteroid approaches, while improved imaging techniques and ultrasound guidance have increased the precision and safety of injectable interventions. Concurrently, minimally invasive surgical techniques, particularly arthroscopic methods, have refined indications for operative management and reduced convalescence times for appropriate candidates.

Complementing therapeutic innovation, digital health enablers such as tele-rehabilitation platforms, remote monitoring, and patient-facing education tools have extended the reach of physical therapy and self-management programs. These tools are increasingly integrated into care pathways to support adherence to exercise therapy, facilitate clinician oversight, and provide real-time feedback on recovery trajectories. On the payer and provider sides, value-based contracting and outcome-focused procurement pressures are incentivizing evidence generation and cost-effectiveness studies, which in turn shape adoption patterns. Finally, supply chain volatility and an increased emphasis on domestic resilience are causing manufacturers and health systems to reassess sourcing strategies for implants, injectables, and home-care devices. Taken together, these shifts are moving the field toward more personalized, data-driven, and care-continuum-oriented approaches that prioritize measurable functional outcomes and patient experience.

How recent United States tariff measures are reshaping procurement, pricing pressures, supply resilience, and therapeutic availability across bursitis care pathways

Recent tariff changes in the United States have reverberated through the medical supply and pharmaceutical value chains, producing cumulative effects that influence treatment availability, procurement practices, and cost structures. Tariffs that affect imported medical devices, injectables, and biologic inputs increase the landed cost of certain products, prompting supply chain actors to reassess sourcing strategies. Consequently, some manufacturers and distributors have accelerated diversification of supplier networks, considered nearshoring or reshoring critical components, and negotiated alternative commercial terms to preserve margins and maintain consistent availability to providers.

Clinically, these procurement responses can influence the mix of therapies offered: higher device or biologic costs may lead health systems and outpatient centers to re-evaluate formularies and standard operating procedures, favoring therapeutics with stronger cost-effectiveness evidence or lower logistic complexity. For home-care modalities and over-the-counter products, tariff-driven price pressures can affect retail pricing and patient out-of-pocket burdens, which in turn shape adherence to noninvasive regimens. Additionally, tariff-induced cost volatility encourages buyers to leverage longer-term contracting, group purchasing organizations, and strategic inventory buffering to mitigate disruption.

At a strategic level, renewed policy-driven cost pressures stimulate investment in domestic manufacturing capacity, increase interest in alternative materials and technologies that bypass tariffed inputs, and intensify collaboration between clinicians, supply chain managers, and procurement teams. While tariffs do not directly change clinical efficacy, their secondary effects on availability, pricing, and procurement behavior can alter the landscape in which therapeutic choices are made, emphasizing resilience, evidence-backed value, and strategic contracting as key mitigation levers.

Clear segmentation-driven insights into therapeutic modalities, product classes, anatomical applications, and care settings that explain adoption patterns and clinical workflows

A granular segmentation lens reveals important nuances in how treatments are applied, which stakeholders are most active, and where innovation is concentrated. When treatments are viewed through the prism of therapy modality, care ranges from home-based measures-such as ice therapy, rest and immobilization, and warm compress applications-through pharmacologic approaches that include both over-the-counter and prescription nonsteroidal anti-inflammatory drugs, to injectable therapies where corticosteroid injections remain a mainstay and emerging options include hyaluronic acid and platelet-rich plasma therapy. Physical therapy practices encompass cryotherapy, exercise therapy, and manual therapy, while surgical interventions are generally divided between arthroscopic and open surgical approaches. Each of these subsegments demonstrates distinct patterns: conservative home care and oral medication often serve as initial steps that prioritize accessibility and low cost, whereas injectable therapy and surgical intervention are typically pursued when symptoms persist or functional goals demand more aggressive management.

From a product-category perspective, antibiotics, biologics, corticosteroids, and nonsteroidal anti-inflammatory drugs play discrete roles with differing regulatory profiles, evidence requirements, and distribution pathways. Biologics and advanced regenerative products, for example, require distinct cold-chain logistics and clinical training for administration compared with small-molecule NSAIDs. Considering anatomical application sites, treatment selection is influenced by structural variation across the elbow, heel, hip, knee, and shoulder; site-specific biomechanical demands and patient activity levels drive clinical decision-making and rehabilitation planning. Finally, the end-user landscape spans ambulatory surgical centers, home care settings, hospitals, orthopedic clinics, and sports medicine centers, each with unique purchasing processes, clinical workflows, and volume profiles. Understanding how these segmentation axes interact is essential for tailoring clinical protocols, commercial strategies, and evidence-generation programs to real-world use cases.

Key regional distinctions in practice patterns, reimbursement realities, regulatory pathways, and supply chain factors that influence clinical adoption across major global markets

Regional dynamics materially influence how bursitis is diagnosed, treated, and reimbursed, with distinct patterns emerging across major geographies. In the Americas, care delivery often emphasizes rapid access to interventional procedures and well-established outpatient pathways; private payer mix and ambulatory surgical center growth shape the distribution of injectable therapies and arthroscopic procedures. Moving to Europe, Middle East & Africa, practice variation is greater due to heterogeneous reimbursement systems, regulatory regimes, and access to advanced biologics; in many markets, centralized procurement and national guideline alignment influence the uptake of higher-cost therapeutics, and public systems play an outsized role in defining standard of care. Across the Asia-Pacific region, demographic trends-such as rapidly aging populations in some countries and high sports participation in others-drive demand for both conservative and interventional approaches, while manufacturing hubs and regional supply chains influence availability and pricing dynamics.

Across all regions, the pace of digital adoption, tele-rehabilitation, and training for ultrasound-guided injections varies, affecting the extent to which remote care or image-guided interventions are integrated into routine practice. Moreover, regional regulatory pathways for novel biologics and cell-based therapies determine the speed with which evidence is translated into clinical availability. Trade policies and logistics infrastructure further modulate the reliability of product supply, and regional differences in clinical guideline development and specialist density shape where care is concentrated, whether that be in hospital systems, specialty clinics, or community-based settings.

Insightful analysis of competitive roles, strategic partnerships, and evidence-driven differentiation shaping the commercial landscape for bursitis therapeutics and services

Competitive dynamics within the bursitis treatment ecosystem reflect a heterogeneous mix of established pharmaceutical manufacturers, medical device companies, specialty biologics and regenerative medicine developers, digital health vendors, and service providers that support distribution and clinical training. Incumbent players continue to leverage scale, clinical relationships, and broad product portfolios to maintain access across hospitals and ambulatory centers, while smaller specialty firms focus on niche innovations-particularly in regenerative injections, point-of-care biologic processing, and novel delivery systems. At the same time, digital therapeutics and tele-rehabilitation suppliers are increasing their relevance by enabling long-term adherence to exercise therapy and facilitating remote clinician oversight.

Strategic behavior includes targeted partnerships between device or biologic developers and clinical networks to generate real-world evidence and to accelerate guideline adoption. Contract manufacturing organizations and logistics specialists also play a pivotal role, particularly for temperature-sensitive biologics and single-use procedural kits. Across the competitive landscape, differentiation increasingly depends on the strength and transparency of clinical evidence, the quality of training and clinician support programs, and the ability to demonstrate consistent outcomes in routine practice. Companies that can integrate evidence generation with pragmatic implementation support, while also addressing payer concerns regarding cost-effectiveness, are positioned to gain preferential access to procurement decision-makers and long-term contracts.

Practical and evidence-focused strategic recommendations for manufacturers, providers, and payers to enhance clinical value, supply resilience, and patient-centered outcomes

Industry leaders and clinical program directors should adopt a multi-pronged strategy to capture clinical value, improve patient outcomes, and mitigate commercial risk. First, prioritizing high-quality evidence generation for novel injectables and regenerative options is essential; randomized controlled trials complemented by pragmatic real-world studies will support payer engagement and guideline inclusion. Second, diversifying supply chains and exploring nearshoring options for critical components can reduce exposure to tariff volatility and shipping disruptions, while strategic contracting with group purchasers can stabilize pricing and availability. Third, investing in clinician education and structured implementation programs for ultrasound-guided injections and minimally invasive procedures will facilitate appropriate adoption and reduce variability in outcomes.

Additionally, integrating tele-rehabilitation and patient-facing adherence tools into care pathways can improve functional recovery rates and reduce downstream utilization of invasive procedures. Value-based contracting models that link reimbursement to patient-reported outcomes and functional benchmarks should be explored with payers to align incentives around meaningful recovery. Finally, companies and providers should develop clear, patient-centered communication frameworks to set expectations for recovery timelines, nonpharmacologic management, and the trade-offs between short-term symptom relief and longer-term tissue healing, thereby enhancing shared decision-making and adherence to conservative regimens when appropriate.

A rigorous mixed-methods research methodology combining expert interviews, clinical literature synthesis, supply chain analysis, and utilization data triangulation to ensure robust findings

The research underpinning these insights combined a layered methodology designed to triangulate clinical practice patterns, procurement behaviors, and innovation trends. Primary inputs included structured interviews with orthopedists, physiotherapists, interventional pain specialists, ambulatory surgery managers, and payer medical directors to capture frontline perspectives on treatment selection, barriers to adoption, and operational constraints. Secondary analysis drew upon peer-reviewed clinical literature, professional society guidelines, and regulatory filings to assess the comparative evidence base for pharmacologic, injectable, rehabilitative, and surgical approaches. Supply chain mapping and trade data reviews were used to understand sourcing vulnerabilities and the potential impacts of tariff shifts on component availability.

Wherever possible, qualitative findings were cross-checked with anonymized claims and utilization datasets to validate patterns of service delivery and care transitions. The methodology prioritized transparency about limitations: for example, national-level heterogeneity in coding practices can complicate cross-country comparisons, and emerging biologic technologies may lack long-term outcome data. Ethical safeguards included informed consent for interviews and de-identification of proprietary procurement information. Taken together, this mixed-methods approach offers a robust foundation for the insights presented while acknowledging areas where further prospective data collection would strengthen causal inference.

Concluding synthesis highlighting the intersection of clinical innovation, care delivery transformation, payer pressures, and supply resilience shaping future bursitis care

In summary, the management of bursitis is being reshaped by converging forces: therapeutic innovation in biologics and image-guided interventions; expanding capability for remote and home-based care; heightened payer emphasis on outcomes and cost-effectiveness; and supply chain pressures that influence product availability and pricing. These dynamics create both challenges and opportunities for stakeholders across the clinical and commercial spectrum. Clinicians are tasked with integrating new modalities while maintaining evidence-based pathways, manufacturers must demonstrate clear comparative value, and health systems need to design resilient procurement strategies that support consistent access to a full continuum of care.

Moving forward, the most successful programs will be those that align rigorous clinical evidence with pragmatic implementation supports, leverage digital tools to enhance recovery and adherence, and proactively manage supply risk through diversified sourcing and strategic contracting. By focusing on measurable functional outcomes and patient-centered care, stakeholders can improve recovery trajectories while ensuring sustainable delivery models that are responsive to evolving regulatory and commercial conditions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising use of ultrasound-guided corticosteroid injections to improve bursitis treatment precision
  • 5.2. Expansion of minimally invasive needle fenestration techniques to accelerate bursa healing and reduce recovery time
  • 5.3. Development of novel hyaluronic acid formulations targeting shoulder and hip bursitis pain relief with longer duration
  • 5.4. Integration of wearable motion sensors for real-time monitoring of joint stress in bursitis rehabilitation protocols
  • 5.5. Increasing interest in platelet-rich plasma therapies for refractory bursitis cases among sports medicine practitioners
  • 5.6. Growth of home-use cold compression systems enhanced by smart temperature control to manage bursitis inflammation

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bursitis Treatment Market, by Treatment Type

  • 8.1. Home Care
    • 8.1.1. Ice Therapy
    • 8.1.2. Rest Immobilization
    • 8.1.3. Warm Compress
  • 8.2. Injectable Therapy
    • 8.2.1. Corticosteroid Injections
    • 8.2.2. Hyaluronic Acid Injections
    • 8.2.3. Platelet-Rich Plasma Therapy
  • 8.3. Oral Medication
    • 8.3.1. Over-The-Counter Nonsteroidal Anti-Inflammatory Drugs
    • 8.3.2. Prescription Nonsteroidal Anti-Inflammatory Drugs
  • 8.4. Physical Therapy
    • 8.4.1. Cryotherapy
    • 8.4.2. Exercise Therapy
    • 8.4.3. Manual Therapy
  • 8.5. Surgical Intervention
    • 8.5.1. Arthroscopic Surgery
    • 8.5.2. Open Surgery

9. Bursitis Treatment Market, by Product Category

  • 9.1. Antibiotics
  • 9.2. Biologics
  • 9.3. Corticosteroids
  • 9.4. Nonsteroidal Anti-Inflammatory Drugs

10. Bursitis Treatment Market, by Application Site

  • 10.1. Elbow
  • 10.2. Heel
  • 10.3. Hip
  • 10.4. Knee
  • 10.5. Shoulder

11. Bursitis Treatment Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Home Care Settings
  • 11.3. Hospitals
  • 11.4. Orthopedic Clinics
  • 11.5. Sports Medicine Centers

12. Bursitis Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Bursitis Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Bursitis Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Pfizer Inc.
    • 15.3.2. Bayer AG
    • 15.3.3. Johnson & Johnson
    • 15.3.4. Novartis AG
    • 15.3.5. Teva Pharmaceutical Industries Ltd.
    • 15.3.6. GlaxoSmithKline plc
    • 15.3.7. Sanofi S.A.
    • 15.3.8. Merck & Co., Inc.
    • 15.3.9. Zimmer Biomet Holdings, Inc.
    • 15.3.10. Stryker Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BURSITIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. BURSITIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BURSITIS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BURSITIS TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ICE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REST IMMOBILIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY WARM COMPRESS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROID INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HYALURONIC ACID INJECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PLATELET-RICH PLASMA THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OVER-THE-COUNTER NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRESCRIPTION NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CRYOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY EXERCISE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY MANUAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ELBOW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HEEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HIP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY KNEE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SHOULDER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY ORTHOPEDIC CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY SPORTS MEDICINE CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL BURSITIS TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE BURSITIS TREATMENT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE BURSITIS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE BURSITIS TREATMENT MARKET SIZE, BY HOME CARE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE BURSITIS TREATMENT MARKET SIZE, BY INJECTABLE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE BURSITIS TREATMENT MARKET SIZE, BY ORAL MEDICATION, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE BURSITIS TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE BURSITIS TREATMENT MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE BURSITIS TREATMENT MARKET SIZE, BY APPLICATION SITE, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE BURSITIS TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE BURSITIS TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)

TABLE